SpringWorks Therapeutics Showcases Advancements in Targeted Oncology Portfolio at Virtual R&D Day
Post contains more than 1000 words. Please wait for the next step for the completion of the response. Effect on Individual Patients: For individual patients, the NDA filing for Nirogacestat in Desmoid Tumors being reviewed under the RTOR program by the FDA is significant news. Desmoid tumors are rare, slow-growing tumors that can be challenging…